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Skin and soft tissue infections (SSTIs) affect millions of individuals worldwide, every year. 
SSTIs vary in complexity and severity, ranging from superficial skin infections such as impetigo to 
more severe, polymicrobial, biofilm-forming bacterial infections that establish in chronic wounds or 
burns. Prevalent bacterial isolates found in simple and complex SSTIs are Staphylococcus aureus and 
Pseudomonas aeruginosa, respectively. Antibiotics are commonly prescribed to treat simple SSTIs, 
however the emergence of multi-drug resistant bacterial strains and the intrinsic antibiotic resistance 
of biofilms make complex SSTIs more difficult to treat. The increased clinical demand has 
spearheaded the search for novel antimicrobials from natural sources. Seaweeds have adapted to 
competition and predation by producing secondary metabolites, some of which exhibit antimicrobial 
activity. The aim of this project was to investigate the antimicrobial and anti-biofilm activity of a 
lipid- and pigment-rich extract from Macrocystis pyrifera (giant kelp). 
 A chloroform:methanol (CHCl3:MeOH) extraction of M. pyrifera seaweed was performed. 
The agar diffusion assay was then used to determine the antimicrobial activity of this extract against 
clinically relevant S. aureus and P. aeruginosa. A zone of inhibition (ZOI) against S. aureus LAC 
USA300 (14.73 ± 0.33 mm) and S. aureus Newman (13.37 ± 3.36 mm) was observed with the extract 
when in a MeOH vehicle, but no activity was evident against P. aeruginosa. In a biofilm eradication 
assay, treatment with the extract led to a decrease in the bacterial number of S. aureus Newman and 
LAC USA300. To isolate active compounds within the extract, single column fractionation with 
CHCl3 and MeOH was performed. Fraction 24 (in MeOH) showed antimicrobial activity, with ZOI 
observed against S. aureus LAC USA300 (16.75 ± 2.47 mm) and S. aureus Newman (16.99 ± 1.39 
mm).  
These findings indicate that M. pyrifera extract and fraction 24 possess antimicrobial activity 
against strains of S. aureus and may have utility in the treatment of SSTIs. Further analysis is however 
needed to comprehensively identify which compounds within this seaweed are responsible for its 
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At ~1.8 m2, the skin is the largest organ of the human body. Its primary function is to act as a 
physical and biological barrier, protecting us from assault from pathogenic, chemical and physical 
dangers (1). The entire surface of the skin is densely colonised by a huge variety of microorganisms 
including bacteria, viruses and fungi, thus making up the skin microbiota. The skin provides a number 
of ecological niches for microbial habitation, allowing colonised microbes to provide protection 
against pathogens, forming a commensal relationship between human and microorganism. Generally, 




Physical and biochemical features of the skin act to protect against an overabundance of 
commensal organisms and from colonisation of pathogenic microbes (1). The skin is made up of three 
layers, superficial to deep, the epidermis, dermis and hypodermis (Figure 1). The epidermis provides 
the physical protective barrier between the external environment and interior of the body. The stratum 
corneum is the outermost layer of the epidermis, it serves as the primary barrier to the external 
environment, and is comprised of terminally differentiated, enucleated corneocytes. These are 
routinely shed due to constant self-renewing properties, thereby protecting the skin from harmful 
organisms and toxins (1, 2). The dermis is a network of collagen and elastin fibres, fibroblasts and 
nerve endings, all together providing the elasticity and strength of  the skin (3). The hypodermis is a 
layer of adipose tissue and muscle which aid the skin’s thermoregulation and strength (1) (Figure 1). 
Other protective features of the skin include its cool, acidic, and salty nature. The temperature of the 
skin ranges from 29C to 34C and when combined with a pH of 4.5 – 5.5, providing an unfavorable 
environment for many pathogenic bacteria to colonise (1). Sweat glands are an essential feature, and 




Figure 1. Cross sectional illustration of human skin.  
a) normal non-diseased human skin. b) polymicrobial biofilm infection on a skin 
wound. Three skin layers are indicated. Images prepared on BioRender. 
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Eccrine glands, the most common form of sweat glands, are responsible for acidification of the 
skin, and modulate colonisation and growth of microbes through creating different pH levels 
across the skin (1). Another feature of skin are sebaceous glands, these are connected to the hair 
follicle and secrete a lipophilic substance called sebum. Sebum is hydrophobic and protects the 
hair and skin by acting as an antimicrobial shield (1).  
Topography, site, host and environmental factors all contribute to the skin environment, 
which results in differences within the microbiota at different areas of the body, as well as 
between people (2). Interestingly, genetic sequencing shows larger variation in bacteria 
between skin sites on individuals, than in bacteria at the same skin site between individuals (2). 
Thus, different niches are greater determinates of the microbiota than interpersonal genetic 
variation. Areas rich with sebaceous glands such as the forehead are generally low in microbial 
diversity. Propionibacterium ssp. are usually the dominant bacterial species in these areas (1). 
In moist areas, such as, behind the knee and in the elbow crease, Staphylococcus and 
Corynebacterium spp. are determined as the abundant species. Whereas, in dry areas like the 
forearm, there is a wide diversity in bacterial species present (1).  
Commensal bacteria, such as those mentioned above, are defined as microbes that exist 
on the skin in a symbiotic state. However, as environmental conditions change, so can the 
symbiotic relation between microbe and host. Intrinsic factors, such as comorbidities, and 
extrinsic factors, such as implantation of a surgical device like a catheter, can both cause a 
disturbance in symbiosis (4, 5). This change in the skin environment can lead to dysbiosis, an 
imbalance in the skin microbiota, thus contributing to disease. (1). For example, a wound or a 
catheter causes a break in the skin’s physical barrier, which allows commensal bacteria to 
migrate into the wound and begin to multiply, thus creating an overgrowth of bacteria. These 
bacteria are classed as opportunistic pathogens (6). This explains why microorganisms classed 
as commensals are frequently associated with disease states (6).  
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Skin and Soft Tissue Infections 
Skin and soft tissue infections (SSTIs) generally occur in damaged skin and are caused 
by overgrowth of commensal bacteria, or colonisation by pathogenic bacteria (7). SSTIs are 
classified as simple to complex (7). Simple SSTIs are typically mono-microbial, for example 
impetigo, which is an infection caused by Staphylococcus aureus (8). Complex SSTIs tend to 
be polymicrobial, such as Pseudomonas aeruginosa and S. aureus infections found in traumatic 
burn wounds (4, 9). SSTIs are treated empirically so the severity of SSTIs is a common 
guideline used for choosing the appropriate treatment. A simple SSTI may self-resolve or 
require a topical antibiotic, such as fusidic acid (10). An infection that affects deeper dermal 
layers would require systemic antibiotics, such as clindamycin (4, 11).  
 
Antibiotic Resistance and SSTIs 
While some strains of bacteria found within SSTIs are multi-drug resistant, antibiotic 
resistance is also emerging in clinically-relevant strains, thus both are complicating the 
treatment of SSTIs (12). This includes methicillin-resistant S. aureus (MRSA); a S. aureus 
strain that has acquired the mecA gene encoding the penicillin binding protein 2a, providing 
resistance against -lactam antibiotics, such as penicillin (4). MRSA is one of the major causes 
of hospital-associated infections globally, with a mortality rate of around 20% in invasive 
infections (13). P. aeruginosa is a multi-drug resistant, clinically-relevant opportunistic 
pathogen found in SSTIs (4). P. aeruginosa was found to be one of five most prevalent bacterial 
pathogens isolated from SSTIs in the United States, France, Germany, Italy and Spain (14).  P. 
aeruginosa has acquired various intrinsic resistance mechanism against antibiotics. For 
example, the acquisition of hydrolytic enzymes that target -lactams, metallo-carbapenems and 
AmpC-cephalosporins and the upregulation of drug efflux pumps (4, 15).  
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SSTI infections are commonly associated with the presence of biofilms (16), which are 
communities of bacterial cells, including dormant bacteria, aggregated within an extracellular 
matrix (16). Biofilm-forming bacterial infections are difficult to treat as they are up to 1000-
times more resistant to antibiotics (16). The biofilm extracellular matrix prevents antibiotic 
penetration and, due to physical constraints and impaired diffusion of nutrients, reduces 
bacterial metabolism (17). Antibiotics typically target metabolically active, planktonic or free-
living bacteria (17). Thus, metabolically-inactive bacteria within biofilms exhibit greater 
antibiotic resistance (17). To date, there are no biofilm-specific treatments available. 
Antibiotic resistant bacteria are a persistent threat to treating SSTIs (18). Since the 
discovery of the antibiotic daptomycin in 1987 (19), no new antibiotics have reached the 
market, particularly for antibiotics active against Gram-negative bacteria (20). Multi-drug 
resistant pathogens such as P. aeruginosa are commonly isolated from SSTIs and there are only 
a few limited treatment options (21). Carbapenems are considered the last line of defence 
against Gram-negative bacteria, such as P. aeruginosa (22). Therefore, it is concerning that up 
to 50% of resistance against carbapenems has been reported (22). As a result of increased 
antibiotic resistance in both commensal and pathogenic bacteria that cause SSTIs, there is an 
urgent need for new therapeutics. Studies have looked towards solutions to bridge the issue of 
failing antibiotics. Pinto et al. (23) trialed silver cations (Ag+), which disrupt the bacterial cell 
wall and membrane, as a topical antimicrobial treatment. To improve adherence to the wound, 
they delivered Ag+ complexed within a novel soft agar hydrogel. Results found this method of 
application to be successful due to its stability, ease of application and removal and softness 
(23). Several new therapies involve peptide-derived post-translationally modified antimicrobial 
agents, lantibiotics, used alone or synergised with polymyxin to create bactericidal activity (24). 
Lantibiotics, such as nisin or the novel NAI-107, bind to a precursor molecule on the cell wall 
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called lipid II, this then disrupts cell wall synthesis (24). Meanwhile, other novel therapies look 
towards natural products as an exciting, alternative solution towards antibiotic resistance(25).  
Methods for Evaluating Antimicrobial Compounds 
In order to test the potency of novel antimicrobial agents against planktonic bacteria, a 
minimal inhibitory concentration (MIC) assay using microbroth dilution or an agar well 
diffusion methods are performed (26). The MIC is defined as the minimum concentration 
required to inhibit growth of planktonic bacteria, determined by visualisation of bacterial 
growth. A broth microdilution assay involves bacteria being grown in a 96 well plate with the 
addition of antimicrobial compounds (27), with the MIC determined as the concentration of the 
first well that has no bacterial growth (28). A study showed the MIC value of vancomycin 
against three different P. aeruginosa strains (PAO1, PA19660 and PA-OS) was >256 µg/mL, 
indicating resistance (29). Whereas in an agar well diffusion assay, the antimicrobial activity 
of a compound is determined based on the size of the zone of inhibition (ZOI) formed (30). 
With sessile biofilm cultures, an in vitro minimum biofilm eradication concentration (MBEC) 
assay is conducted to obtain the lowest concentration required of a compound to eradicate a 
pre-formed biofilm grown on a surface (26).  Previous literature has found that antibiotics 
cannot appropriately treat biofilm infections (31). To reinforce this concept, the MIC and 
MBEC value for ciprofloxacin against MRSA ATCC 43300, were 0.5 mg/L and 1,280 mg/mL, 
respectively (31).   
 
Seaweed-derived Bioactive Compounds 
Sessile marine organisms, such as seaweed, live in complex environments, coexisting 
with competitors for nutrition and space, as well as other hostile microorganisms (32). To 
ensure their own survival, seaweeds have evolved to produce bioactive secondary metabolites 
that show inhibition towards bacteria, viruses and fungi (32). Seaweeds are highly diverse, 
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being classed as red, brown, or green, with each species producing a variable range and 
concentration of bioactive compounds, which include lipids, pigments, polysaccharides and 
phenols. Other factors that may influence their antimicrobial properties include the geographic 
location of the seaweed, seasonality, light, temperature and salinity (33). Seaweeds with 
antimicrobial properties are now being explored as potential alternative antimicrobial agents in 
the food and pharmaceutical industry (32). A way to slow the development of antibiotic 
resistance is to move away from developing new drugs based off existing synthetic 
antimicrobial compounds (32). Marine organisms possess natural compounds that often differ 
structurally to terrestrial compounds, and as such may interact with novel targets. These 
compounds may therefore have clinical utility, but with less chance of exasperating 
antimicrobial resistance (32).  
 
Extraction Methods 
Previous studies have reported that the antimicrobial potency of seaweed extracts vary 
based in their combination of secondary metabolites (33). The content of a seaweed extract is 
determined by specific factors in the extraction processes. Extraction conditions include the use 
of pre-treatment, type of solvent, drying temperature and extraction parameters, i.e. solid/liquid 
ratio, particle size, time etc. (34). The use of organic solvents result in a more efficient 
extraction due to the hydrophobic nature of compounds like fatty acids (33). The different 
fractions, such as; phlorotannin, lipid and fucoidan, of seaweeds have been extensively studied 
(33). Phlorotannins can be extracted using hexane (34), fucoidans require complex fractionation 
with solvents, distilled water, calcium chloride and hydrochloride acid (35), while lipids are 
extracted using methanol and chloroform (36). Using different methods and solvents will result 





Phenolic compounds are not directly involved with primary processes like 
photosynthesis or cell division of algae, so are classed as secondary metabolites (33). 
Polyphenols are varied in their structure, composition and molecular weights, ranging from 
simple to complex molecules (33). These are further divided into two groups based on their 
structure and differing properties such as, phloroglucinols and phlorotannins (33). Brown 
seaweed extracts with reported antimicrobial activity often contain eckol and dieckol 
phlorotannin sub-groups (25). This includes antibacterial activity against streptomycin resistant 
Listeria monocytogenes (37).  
 
Agal Lipids and Free Fatty Acids 
Algal lipids include phospholipids, glycolipids, and triglycerides; which combined 
comprise of up to 6.73% of the total dry weight of seaweed (33). Fatty acids are found in a 
variety of lipids which are integral in different cellular structures, such as in the photosynthetic 
cell wall and in the chloroplast cell wall (33). Free fatty acids (FFA) can be extracted from these 
algal lipids by host enzymes (33). Fatty acids can be classed as either saturated or unsaturated, 
then further into either monounsaturated or polyunsaturated (38). FFAs are diverse, possessing 
a wide range of pharmacologically beneficial effects including antioxidant, anti-inflammatory 
and antimicrobial activity (33). A seaweed-derived lipid extract containing stearic acid and 
linoleic acid has been shown display potent bactericidal activity against Gram positive cocci, 
including an MRSA strain (39).  Anti-biofilm activity against a preformed MRSA biofilm was 




Carotenoids are bioactive pigments involved in the photosynthesis process of marine 
algae (33). The carotenoid, fucoxanthin, is an orange pigment found in brown algae, belonging 
to the xanthophyll class (40). Previous studies have reported certain brown seaweed extracts 
containing fucoxanthin have many pharmacologically beneficial bioactive effects, such as 
being anti-cancer, anti-inflammatory and antimicrobial (40, 41). A variety of brown seaweeds, 
have been of great interest to those looking to develop new therapeutics for ailments such as, 
SSTIs, as well as inflammatory diseases (42, 43). Seaweed-derived fucoxanthin has 
demonstrated strong antimicrobial properties of the extract against Gram-positive L. 
monocytogenes (43).  
 
Bioactives Compounds from Macrocystis pyrifera 
Macrocystis pyrifera, a giant brown kelp species present in the Pacific Ocean, is of great 
interest as it contains many of the previously reported bioactive compounds, such as, 
polyphenols, lipids and carotenoids (44, 45). However, little is known about the antimicrobial 
and anti-biofilm activity of compounds within M. pyrifera. Although Leyton et al. (44)has 
shown that the phlorotannin fraction of M. pyrifera demonstrated potent antimicrobial effects 
on S. aureus and Bacillus sp.. Recently, a CHCl3:MeOH extraction from M. pyrifera was shown 
to exhibit anti-inflammatory activity on stimulated human keratinocyte and monocyte cell lines, 
suppressing the production interleukin (IL)-1b, IL-8, and monocyte chemotactic protein 
(MCP)-1 (46). This extract was shown to contain the anti-microbial fucoxanthin, stearic acid, 





Table 1. Fatty acid and carotenoid composition of M. pyrifera extract. (46) 
 
Aims and hypothesis 
The aim of this project was to investigate whether the CHCl3:MeOH extract from M. 
pyrifera has antimicrobial and/or anti-biofilm effect on bacterial species associated with SSTIs. 
As this extract contains FFAs and carotenoids, my hypothesis was that this extract will show 
antimicrobial activity against S. aureus and P. aeruginosa consistent with the activity 
Lipid Numbers Common Name  % of Total Lipids 
Saturated   
C12:0 Lauric acid 1.91 ± 2.20 
C16:0 Palmitic acid 17.65 ± 5.97 
C18:0 Stearic acid 2.87 ± 0.94 
Monounsaturated  
C16:1 Palmitoleic acid 2.28 ± 0.21 
Polyunsaturated  
C18:2n-6 Linoleic acid 5.90 ± 2.00 
C18:3n-6 𝛾 – linoleic acid 6.93 ± 0.32 
C20:4n-6 Arachidonic acid 10.90 ± 4.36 
Omega-3  
C18:3n-3 𝛼 – linolenic acid 7.28 ± 3.24 
 
Unknown  10.686 ± 4.926 
  
Carotenoids Total Concentration (mg/mL) % of Total Dry Weight 
Fucoxanthin 1.00 4.00 
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previously demonstrated for these compounds. However, little is known about the anti-biofilm 
effects of FFAs and carotenoids, so the effects of the extract on S. aureus and P. aeruginosa 
biofilms must be explored. My specific objectives were:  
 
1. To determine whether the M. pyrifera extract possess antimicrobial activity in broth 
microdilution and agar diffusion assays.  
 
2. To evaluate whether the M. pyrifera extract has anti-biofilm properties against biofilms 
in a minimum biofilm eradication concentration screen.  
 
3. To establish whether FFAs or fucoxanthin within the M. pyrifera extract are responsible 
for any antimicrobial or anti-biofilm activity, through extract fractionation, chemical 
characterisation, and assessment of the fractions as described above. 
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Materials and Methods  
Extraction of M. pyrifera 
A 1:1 mix was prepared from commercial M. pryifera kelp granules (KiwiWakame, 
New Zealand) and fresh dried M. pryifera collected fresh from Wellers Rock, Otago, New 
Zealand in October 2018. A mix was used due to lack of supply of fresh seaweed. The extraction 
was performed according to methods in Susanto et al. 2015 (36). Briefly, macerated seaweed 
fronds were soaked in a 2:1 MeOH:CHCl3 solution for three hours in the dark at 180 rpm in 
37°C on a plate shaker. A 0.9% NaCl solution was added to create phase separation. The solvent 
was removed using a rotatory evaporator at 45ºC. The concentrated extract was collected and 
air-dried overnight. Five independent extractions were conducted and stored at -20°C. The 
extract was resuspended in either MeOH, CHCl3, dimethyl sulfoxide (DMSO) or ethanol 
(EtOH) (10 mg/mL and 100 mg/mL) as vehicles.   
 
Bacterial Assays  
Bacterial Strains and Growth Conditions 
The strains of bacteria used were S. aureus LAC USA300 (Los Angeles CA-MRSA 
Isolate Strain), a community acquired methicillin-resistant strain of S. aureus (47), S. aureus 
Newman (48), P. aeruginosa PA14 (49), and P. aeruginosa LESB58 (Liverpool Epidemic 
Strain Isolate) (50). Bacterial strains were streaked from frozen stocks on Muller Hinton Agar 
(MHA) (Oxoid®, United Kingdom) and incubated overnight at 37°C prior to use in an 
experiment. Growth of bacteria was measured according to optical density at 600 nm with an 




All bacterial strains were grown on MHA. Muller-Hinton Broth (MHB) and Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Gibco®, ThermoFisher Scientific, +D-Glucose, L-
Glutamine, -Pyruvate), with 5% foetal bovine serum (FBS) (Gibco, United States) and 1% 
glucose were used.  
 
Minimum Inhibitory Concentration Assays 
Broth Microdilution Assay  
Broth microdilution assays were conducted according to NCCLS standard (51). 
Bacterial cultures were grown on MHA at 37°C for 20 hours. Bacteria were resuspended in 
MHB and bacterial density adjusted to OD600 of 0.002 corresponding 2x106 CFU/mL. The 
adjusted bacterial suspension was inoculated into a 96 well plate prepared with two-fold serial 
microdilutions of antibiotic, extract (10 mg/mL) and vehicle controls were prepared in a flat 
bottom 96 well plate (Greiner Bio-One, Austria). Antibiotics used were polymyxin B, 
vancomycin and ciprofloxacin (all 10 mg/mL). Commerical fucoxanthin dissolved in methanol 
(10 mg/mL) (Sigma Aldrich, Germany) was used as a positive control. The 96 well plate was 
then incubated at 37°C overnight. The MIC of the treatment was taken as the first well with no 
visible bacterial growth. 
 
Agar Diffusion Assay 
Bacterial cultures were streaked on MHA followed by incubation at 37°C for 20 hours. 
The next day, fresh MHA was prepared and cooled in a water bath to 50°C. Bacteria were 
suspended in MHB and mixed with MHA to an adjusted OD600 of 0.1, corresponding to 1x108 
CFU/mL. MHA was mixed with the bacterial suspension, poured into petri dishes, and allowed 
to solidify. A 5 mm diameter hole was then punched into the agar using the larger end of a 
 23 
sterile pipette tip. Imipenem (5 mg/mL; 50 µl), crude extract (in MeoH) (10 mg/mL; 50 µl), 
fucoxanthin (1 mg/mL; 50 µl) or vehicle controls were added into the wells. Agar plates were 
incubated overnight at 37°C. The zone of inhibition was measured as the square root of two 
different measurements of zone of inhibition diameter.   
𝑍𝑜𝑛𝑒 𝑜𝑓 𝐼𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = √𝐷𝑖𝑎𝑚𝑒𝑡𝑒𝑟𝐴 ×  𝐷𝑖𝑎𝑚𝑒𝑡𝑒𝑟 𝐵  
 
Minimum Biofilm Eradication Concentration Screen 
Bacterial cultures were streaked the day prior and grown on MHA at 37°C for 20 hours. 
Bacteria was suspended in MHB and adjusted to an OD600 of 0.1, corresponding to 1x108 
CFU/mL. Bacterial suspension (100 µL) was transferred into the inner wells of a flat bottom 
96 well plate. The outside wells were filled with sterile dH2O. The 96 well plate was incubated 
overnight at 37°C. Following incubation, the supernatant was removed, and the wells were 
washed 5 times with sterile phosphate-buffered saline (PBS) buffer. Serial dilutions of extract 
dissolved in MeOH, EtOH, DMSO or CHCl3 or antibiotics were then added to the wells. 
Antibiotics included vancomycin (1 mg/mL stock) for S. aureus, and ciprofloxacin (1 mg/mL 
stock) for P. aeruginosa. Additional wells of bacteria were left untreated. The treated plates 
were incubated overnight at 37°C. The following three methods were used to quantify the 
biofilm growth.  
 
Crystal violet analysis 
After washing off the planktonic bacteria with sterile PBS, 0.1% crystal violet dye 
(Sigma Aldrich) was added to the wells. The plate was placed on a plate shaker (Ratek, 
Australia) at 180 rpm at room temperature (RT) for 20 minutes, then washed 3 - 5 times with 
sterile PBS. To dissolve the dye, 70% EtOH is added. The plate was placed on the plate shaker 
for another 20 min before quantification of biofilm growth with Varioskan Lux plate reader 
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(Thermo Fisher Scientific, United States) with absorbance at OD 595 nm. The change in biofilm 
mass was then calculated and converted into a percentage change.  
 
% change in biofilm growth =  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑒𝑥𝑡𝑟𝑎𝑐𝑡) 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙) ⁄ ×  100 
 
TTC analysis 
Prior to the treatments described above, 0.1% of 2,3,5-triphenyltetrazolium 
chloride (TTC) dye (5% stock) was added to the MHB. After the second incubation, the plate 
was washed 3-5 times with sterile PBS. MeOH was then added to each well, then the plate was 
placed on a plate shaker at 180 rpm for 20 minutes. Quantification of cell viability was 
determined using a Varioskan Lux plate reader with absorbance at OD 500 nm. To determine 
metabolically active bacteria the OD for each treatment was compared to that of the untreated 
control and converted into a percentage to show percentage change in biofilm growth. 
 
 % change in biofilm growth =  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑒𝑥𝑡𝑟𝑎𝑐𝑡) 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙) ⁄ ×  100 
 
PrestoBlue analysis 
PrestoBlue dye (10 µL, Thermo Fischer Scientific, United States) was added to the wells 
immediately following treatment. Following the second incubation, the plate was then washed 
3-5 times with sterile PBS, with the final wash conducted for 20 minutes at 150 rpm on the 
plate shaker. Quantification of metabolically active bacteria was determined by measuring 
fluorescence using a plate reader with excitation set at 560 nm and emission wavelength at 590 
nm. To determine biofilm growth, the fluorescence for each treatment was compared to that of 




% change in biofilm growth =  
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑒𝑥𝑡𝑟𝑎𝑐𝑡) 
𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙) ⁄ ×  100 
 
CFU analysis 
Following the second incubation step above, the wells were washed, bacteria scraped 
with a cotton swab, resuspended in MHB, and vortexed for 20 seconds. A two-fold serial 
dilution of bacterial suspension was then plated on MHA plates. The plates were incubated at 
37°C overnight before colony enumeration by counting visible bacterial colonies.  
 
Fractionation of Extract 
The extract was separated by fractionation using single column chromatography, 
following the methods by Revathy et al. (52). A glass column, 2 cm in diameter, was packed 
with silica gel. Approximately 5 mL of CHCl3 was used to equilibrate the column before adding 
1 mg/mL of the extract dissolved in methanol. CHCl3 (10 mL), MeOH:CHCl3  (1:1; 10 mL) and 
MeOH (20 mL) were then passed through the column in succession. Forty 1 mL fractions were 
eluted based on polarity, where more polar compounds were eluted with chloroform and the 
more non-polar compounds with methanol. Fractions were air-dried overnight in a fume hood, 
resuspended in MeOH (1 mg/mL) once the solution evaporated, and stored at -20°C. Fractions 
24-32 were used in further antimicrobial experiments. 
 
Identification of the Active Compound within Fraction 24 
Reverse Phase-High Performance Liquid Chromatography to Quantify Fucoxanthin Content 
in Extract 
The fucoxanthin content in the extract was analysed following the method by 
Sivagananam et al. (42). Reverse Phase-High Performance Liquid Chromatography (RP-
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HPLC) was conducted using a Shimadzu Prominence HPLC system with a pump (LC-20AD), 
an auto-sampler (SIL-20A), and a photo-diode array spectrophotometric detector (SPD-M20). 
A two-fold serial dilution (1 mg/mL – 0.0315 mg/mL) of a fucoxanthin analytical standard 
(Sigma Aldrich, Germany) was used as a reference. The evaporated fraction was resuspended 
in filtered methanol through a 0.4 µm syringe filter (ReliaPrep, United States). The fucoxanthin 
content of the fraction was compared to the fucoxanthin content of the reference standard.  
 
Gas Chromatography (GC) Analysis of Fatty Acid Content of Extract 
Fatty acid methyl esters (FAMEs) were prepared from the fraction according to the 
method by Carreau et al. (53). The fraction was first solubilised using dH2O:MeOH:CHCl3 
(2:4:1). A solution of 0.9 % NaCl:solvent (2:1) was then used to separate the fraction which 
was then dried using N2 gas and was then incubated with MeOH + 1% sulfuric acid at 80°C for 
3 hours. Following incubation, a solution of hexane: water (2:1) was mixed with the separated 
fraction, the water layer was then collected for analysis. GC analysis was performed used an 
Agilent Technologies GC system 6890N with a flame ionisation detector and a capillary 
column. GLC463 was used as a reference standard FAME. The FA content within the fraction 
was determined by comparison of the chromatogram of FA standard of the fraction and that of 
the GLC463 reference standard. This experiment was performed by Jaime Mei-Lin Kok, but 
results analysed as part of this thesis.  
 
Statistical Analysis 
Values are expressed as geometric mean ± SD. Data for each biological replicate was 
calculated as the mean of technical replicates. Each experiment was replicated three times 
unless indicated otherwise. Biofilm results are analysed using a Mann Whitney U test to identify 
significant differences between means for different treatment groups. A non-parametric test 
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was chosen over a parametric test due to the large data spread. A value of P < 0.05 was 




Preparation of the M. Pyrifera Extract 
 A MeOH:CHCl3 extraction was conducted to obtain the crude seaweed extract from M. 
pyrifera. The MeOH:CHCl3 solution was evaporated leaving only the dried crude extract. The 
extract was dissolved in CHCl3, EtOH and MeOH. MeOH dissolved the extract well, leaving 
minimal particulates undissolved. The CHCl3 dissolved the viscous extract well but created 
technical issues during the assays. This interfered with the diffusion of the extract and the 
subsequent reading of the plate with a plate reader and therefore, was withdrawn from further 
experiments. The use of EtOH as a solvent of the crude extract was discontinued for the agar 
well diffusion experiment due to its inability to dissolve the extract fully. 
 
 Antimicrobial Activity of M. Pyrifera Extract 
Microbroth Dilution Assays 
MIC assays conducted in MHB or DMEM + 5% FBS +1% glucose. MHB media is 
optimised for bacterial growth whereas DMEM is tissue culture medium specified for cell 
growth. DMEM media was used in order to simulate a more physiological growth condition for 
bacterial cells. For all bacterial strains, the extract dissolved in EtOH or MeOH did not inhibit 
growth of bacteria at the highest concentration (>250 µg/mL). Commercial fucoxanthin was 
included as a positive control based on previous studies (40) that demonstrated antimicrobial 
activity against S. aureus. However, commercial fucoxanthin did not exhibit any antimicrobial 
activity against any of the bacterial strains (>500 µg/ml) (Table 2). 
Minimum inhibitory experiments showed slightly higher MIC values in DMEM 
compared to MHB for most antibiotics. Vancomycin was shown to be the most effective against 
S. aureus LAC USA300 in both MHB and DMEM (MHB: 0.78 µg/mL, DMEM: 3.13 µg/mL). 
(Table 2). S. aureus Newman showed MIC values against vancomycin that were similar in 
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either media. Ciprofloxacin was more efficacious in MHB compared to DMEM (MHB: 0.31 
µg/mL, DMEM: 1.5 µg/mL). S. aureus Newman and LAC USA300 demonstrated resistance 
against polymyxin B (Table 2).  
Both polymyxin B (1.56 µg/mL). and ciprofloxacin (0.31 µg/mL) were effective against 
P. aeruginosa PA14, in particular when MHB was used (Table 2). When DMEM was used, the 
MIC was higher for both (6.25 µg/mL), 4-fold high with polymyxin B and 20-fold higher for 
ciprofloxacin. A similar trend was observed in the results for P. aeruginosa LESB58. 
Polymyxin B was also effective against P. aeruginosa LESB58, particularly in MHB (1.56 
µg/mL), but in DMEM a 4-fold higher MIC value was observed (6.25 µg/mL). However, in 
DMEM media P. aeruginosa LESB58 was not susceptible to ciprofloxacin (>50 µg/mL), but 
ciprofloxacin was effective when conducted in MHB (6.25 µg/mL). Resistance against 
oxacillin and vancomycin was observed in P. aeruginosa PA14 and LESB58 in both MHB and 
DMEM (Table 2). 
 
Agar Well Diffusion Assays 
 Agar well diffusion assays were conducted as an alternative to broth microdilution 
assays (54). Inhibition of S. aureus LAC USA300 growth was observed in the presence of the 
extract (50 µl) through the presence of a ZOI (14.73 ± 0.33 mm) (Table 3). No inhibition was 
observed with the control, confirming the antimicrobial activity was directly related to the 
extract. Similar results were observed in S. aureus Newman with a ZOI present with the extract 
(13.37 ± 3.36 mm). No ZOI was observed with the extract against either P. aeruginosa PA14 
or LESB58. Similar to the broth microdilution assay, the commercial fucoxanthin displayed no 
antimicrobial activity against any of the bacterial strains (Table 3). As the third experimental 
replicate of the agar well diffusion assay was excluded due to outliers, further experimentation 
must be conducted to definitively conclude that extract is antimicrobial. It should also be noted 
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that with some of the replicates, the crude extract did not cause a complete ZOI against the S. 
aureus strains (Figure 2).   
 
Table 2 Minimum Inhibitory Concentration (µg/mL) of the M. pyrifera Extract in Broth  





















S. aureus LAC USA300 
MHB 0.78 125 12.50 >25 >1000  >1000 
DMEM 3.13 62.50 50 >25 >1000 >1000 
S. aureus Newman 
MHB 3.13 500 0.31 >25 >1000 >1000 
DMEM 6.25 62.5 1.56 >25 >1000 >1000 
P. aeruginosa PA14 
MHB >500 1.56 0.31 >25 >1000 >1000 
DMEM >500 6.25 6.25 >25 >1000 >1000 
P. aeruginosa LESB58 
MHB >500 1.56 6.25 >25 >1000 >1000 
DMEM >500 7.81 >50 >25 >1000 >1000 
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Table 3. Zone of Inhibition Values (mm) of the M. pyrifera Extract in Agar Well Diffusion 
Assays. Results shown are the mean +/- SD from two of three replicate experiments. (NI = no 
inhibition). 
1 fraction 25 through to 32 were individually tested  
Antibiotic/Extract  Zone of Inhibition ± SD (mm)  
S. aureus LAC USA300 
MeOH Control  NI 
Extract (MeOH) (10 mg/mL) 14.73 ± 0.33 
Fraction 24 (1 mg/mL) 16.75 ± 2.47 
Fraction 25 – 32 (1 mg/L)1 NI 
Fucoxanthin (1 mg/mL) NI 
Imipenem (5 mg/mL) 27.48 ±0.71 
S. aureus Newman 
MeOH Control  NI  
Extract (MeOH) (10 mg/mL) 13.37 ± 3.36 
Fraction 24 (1 mg/mL) 16.99 ± 1.39 
Fraction 25 – 32 (1 mg/L)1 NI 
Fucoxanthin (1 mg/mL) NI 
Imipenem (5 mg/mL) 38.49 ± 0.70 
P. aeruginosa PA14 
MeOH Control  NI 
Extract (MeOH) (10 mg/mL) NI 
Fraction 24 (1 mg/mL) NI 
Fraction 25 – 32 (1 mg/L)1 NI 
Fucoxanthin (1 mg/mL) NI 
Imipenem (5 mg/mL) 26.75 ± 1.06 
P. aeruginosa LESB58 
MeOH Control  NI 
Extract (MeOH) (10 mg/mL) NI 
Fraction 24 (1 mg/mL) NI 
Fraction 25 – 32 (1 mg/L)1 NI 
Fucoxanthin (1 mg/mL) NI 






Anti-biofilm Activity of M. pyrifera Extract 
To evaluate the anti-biofilm activity of the M. pyrifera extract, MBEC screens were 
performed on 24-hour old preformed biofilms. Preliminary results to determine a solvent that 
did not disrupt biofilm growth showed that MeOH would be the most suitable. Staining of the 
biofilm with TTC dye, a protocol which included a solubilisation step using MeOH, however 
showed interference with extract dissolved in MeOH. Technical difficulties with washing of 
the plate thoroughly following staining of the biofilm with crystal violet dye also prevented 
accurate detection. Therefore, TTC and crystal violet dyes were excluded from the biofilm 
analysis. P. aeruginosa PA14 was also withdrawn from further experiments as preliminary 
MBEC experiments indicated the extract did not have any anti-biofilm activity against this 
strain.  
PrestoBlue analysis showed no difference in biofilm metabolism between the vehicle 
control, biofilm control and the extract in any of the tested bacterial strains (not shown). 
Therefore, quantification of bacterial numbers within the biofilm was performed by colony 
enumeration. The extract showed a non-significant, 1.9-fold decrease in the number of S. aureus 
Newman bacteria in the biofilm, compared to that of the MeOH control (Figure 3). A non-
significant 2.2-fold decrease in bacterial numbers was also observed for extract treated S. 
Figure 2. Photograph of incomplete zone of inhibition for S. 
aureus Newman in the presence of the M. pyrifera extract in a 
well agar diffusion assay.  
Scale bar = 5 mm. Arrow indicates the change between complete 




aureus LAC USA300. The extract showed no anti-biofilm activity towards P. aeruginosa 
LESB58, with a 2-fold increase relative to the control (Figure 3).  
Fractionation of M. Pyrifera Extract 
Since the extract dissolved in MeOH was found to show antimicrobial and anti-biofilm 
activity against S. aureus strains, this extract was further fractionated using single column 
chromatography, in order to identify and isolate the active compound. Out of the 40 fractions 
isolated from the extract, fractions 24 - 32 were chosen based on their pigmentation (43). 
Fraction 24 - 32 were then subjected to agar well diffusion assays in order to test for 
antimicrobial activity against S. aureus and P. aeruginosa. 
 
Figure 3.Quantification of bacteria within biofilms (CFU/mL) following treatment with the 
M. pyrifera extract in the MBEC assay.  
Symbols indicate the values from each of three replicate experiments for S. aureus Newman 
(a), S. aureus LAC USA300 (b) and P. aeruginosa LESB58 (c), with the median for each 
indicated by a line. Concentration of extract (MeOH): 10 mg/mL Results were analysed using 
a Mann Whitney U test.  
.  
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Antimicrobial Activity of M. pyrifera Fractions 
Agar Well Diffusion Assay 
Fraction 24 showed antimicrobial activity against both S. aureus strains (Newman: 
16.75 ± 2.47 mm and LAC USA300: 16.99 ± 1.39 mm), but not against P. aeruginosa (Table 
3). The observed ZOI was slightly larger than that for the original extract (Newman: 14.73 ± 
0.33 mm and LAC USA300: 13.37 ± 3.36 mm). There was no ZOI for fractions 25 to 32 against 
any of the tested bacterial strains (Table 3).  
 
Composition of Fraction 24 
 Next the compounds within fraction 24 were analysed, to identify the source of the 
antimicrobial action. Fucoxanthin content was assessed using RP–HPLC, while the lipid 
content was detected using GC.   
 RP–HPLC analysis showed a large peak at retention time 10.422 minutes for the 1 
µg/mL fucoxanthin reference standard when measured at 450 nm wavelength. Fraction 24 
(0.997 µg/mL) did not show any peak at this time point (Figure 4).  
 The chromatogram for GLC463 FAMEs reference standard showed the presence of 
peaks that represent FFAs within the standard (Figure 5). This was then compared with the 
chromatogram of fraction 24 in order to identify whether FFAs were present. The 
chromatogram for GLC463 FAMEs reference standard showed strong peaks for palmitic acid 
(C16:0), stearic acid (C18:0), palmitoleic acid (C16:1), linoleic acid (C18:2n6), 𝛾-linolenic acid 
(C18:3n6),  𝛼-linolenic acid (C18:3n3) and arachidonic acid (C20:4n6) (Figure 5). In 
comparison, the chromatogram for the active fraction showed a strong peak for palmitic acid, 
while the peaks for stearic acid, palmitoleic acid, linoleic acid, 𝛼-linolenic acid and 𝛾-linolenic 


























































































































































































































































































































































































































































































































































































































































































































































The emergence of multi-drug resistant bacteria, which are clinically relevant in SSTIs, 
has created a demand for novel antimicrobial therapeutics (19). To overcome the discovery 
void of functioning antimicrobials, several different pathways have been explored. Previous 
studies have looked at different mechanisms and methods of drug administration, antimicrobial 
peptides and, pivotally, natural products (23, 24, 44, 55). Seaweeds produce secondary 
bioactive metabolites that have previously shown to have pharmacologically beneficial 
properties, such as antimicrobial activity (33). This project demonstrated that a MeOH:CHCl3 
extract and fraction from the brown seaweed, M. pyrifera, exhibits antimicrobial and to some 
extent anti-biofilm activity against S. aureus, a bacteria present in both simple and complex 
SSTIs.  
These findings are consistent with previous studies that have reported antimicrobial 
activity for various seaweed extracts (Table 4). Leyton et al. (44) showed that a water fraction 
from a M. pyrifera extract had antimicrobial effects on S. aureus. Kim et al. (37) demonstrated 
that an ethyl acetate fraction of the brown algae, Eisenia bicyclis, had antibacterial activity 
against L. monocytogenes (37). Both of these extracts were shown to contain phlorotannins, 
which were not specifically examined in the M. pyrifera extract or fractions evaluated here. 
Fucoxanthin, purified from Himanthalia elongata using low polarity solvents and thin layer 
chromatography, demonstrated strong antimicrobial activity against L. monocytogenes (43). 
Although fucoxanthin was detected in the M. pyrifera extract (46), it was not detectable in 
fraction 24, indicating it is not responsible for the activity seen against S. aureus. Ethyl acetate 
fractions of an extract from Chaetomorpha cressa, a green algae, showed antibacterial activity 
and anti-biofilm activity against MRSA and S. aureus strains (39). This activity was attributed 
to the presence of FFA, specifically stearic acid and linoleic acid. The M. pyrifera extract and 
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fraction 24 evaluated in this study also contained FFAs, but stearic acid and linoleic acid were 
not the most abundant lipids.  





Bacterial Strain Antimicrobial 
Assay 
MIC (µg/mL) or 
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5.3 ± 0.1 mm 
Clinical isolates of 
P. aeruginosa 






FFAs (50 µg) S. aureus Newman Agar Disk 
Diffusion 
13.37 ± 3.36 mm 
S. aureus LAC 
USA300 
14.73 ± 0.33 mm  
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In this project, the antimicrobial activity of the extract and the isolated fraction was 
evaluated with different MIC assays. No antimicrobial activity was observed from the extract 
using the broth microdilution assay against any of the bacterial strains. However, the agar well 
diffusion results suggested that both the extract and fraction 24 had antimicrobial activity 
against S. aureus strains. As phlorotannin, fucofuroeckol-A, purified from E. bicyclis, showed 
a MIC of 16 µg/mL against L. monocytogenes strain 2148 in the broth microdilution assay (37) 
(Table 4), this suggests phlorotannins may not be present in the M. pyrifera extract or fraction, 
or that they do not target S. aureus. Indeed, a phlorotannin extract from M. pyrifera showed 
only marginal activity against S. aureus ATCC 25923 in a disk diffusion assay (44)(Table 4). 
By contrast, the ethyl acetate FFA-fractions (50 µg) from C. cressa caused a ZOI against MRSA 
ATCC 4827 (24.00 ± 1.00 mm) and S. aureus ATCC 25923 (28.67 ± 1.56 mm) in the disk 
diffusion assay (39) (Table 4). The lipophilic crude extract of M. pyrifera (50 µg), of this study 
demonstrated antimicrobial activity against methicillin resistant S. aureus LAC USA300 
(extract: 14.73 ± 0.33 mm) and the methicillin sensitive S. aureus Newman (extract: 13.37 ± 
3.36 mm) (Table 4). When isolated, fraction 24 demonstrated better antimicrobial activity 
compared to the crude extract in the well diffusion assay against both S. aureus strains (S. 
aureus LAC USA300; extract: 14.73 ± 0.33 mm vs fraction 24: 16.75 ± 2.47 mm) (S. aureus 
Newman extract: 13.37 ± 3.36 mm vs fraction 24: 16.99 ± 1.39 mm). Although, the agar well 
diffusion assay must be repeated to definitively conclude the antimicrobial activity of the 
extract.  
However, some replicates of the agar well diffusion also did not produce a complete 
zone of inhibition. This may be due to solubility issues with the active component interfering 
with diffusion through the agar. Another reason may be there are more than one active 
component with differing solubilities, thus, the rate of diffusion through the agar is different.  
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A major inconsistency in this study was that, in contrast to the agar well diffusion assay, 
the microbroth dilution assay did not yield any results suggesting the extract was antimicrobial 
against any of the bacterial strains. However, this is likely due to a higher amount of extract 
used in the agar well diffusion assay compared to the broth microdilution assay. The broth 
microdilution assay did, however, produce results for the antibiotic controls that were consistent 
previous reports. Polymyxin B has been reported to have bactericidal activity against Gram-
negative bacteria, such as P. aeruginosa, but have no activity against Gram-positive bacteria 
like S. aureus (57). This aligns with the results from this study. Previous literature has also 
described discrepancies between broth microdilution and agar diffusion methods (54). Baker et 
al. (54) found the MIC values for certain antibiotics, such as oxacillin and imipenem, obtained 
from the broth microdilution assay were generally higher than that from the agar diffusion 
experiment. A suggested cause for the discrepancies was resistant mutants are more apparent 
in broth microdilution assays due to continued growth of the bacteria, whereas, a few resistant 
CFUs in an agar dilution assay can be undetectable (54). Although the study by Baker et al. 
had slight methodology differences to that of this project, such as a lower bacterial inoculum 
and the antibiotics were spotted on the agar instead of in a well, the findings and reasonings 
may still comparable to this project.  
The anti-biofilm activity of the extract was further explored in this project. The 
PrestoBlue dye quantification showed that there was no significant difference in biofilm 
metabolism following treatment with the extract in any of the bacterial strains. Quantification 
of biofilm density by colony enumeration showed a non-significant 1.9-fold decrease in 
bacterial number within S. aureus Newman biofilms, and a decrease of 2.2-fold in bacterial 
number was observed in S. aureus LAC USA300 biofilms, with the extract compared to the 
control. Therefore, the anti-biofilm effect of the extract against the S. aureus strains cannot be 
confirmed. Anti-biofilm activity has, been reported for a FFA-rich extract from C. cressa, 
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which significantly decreased a preformed MRSA ATCC 4827 biofilm by 78% (39). This 
discrepancy between finding a statistically significant decrease in biofilm formation could be 
due to the different strains of MRSA used, or the methodology differences, Ramkissoon et al. 
quantified biofilm mass using CV due whereas this study used colony enumeration.  
Interestingly, the crude extract exhibited antibiofilm activity but failed to show 
antimicrobial activity in the microbroth dilution assay. This may be owed to the mechanism of 
action of the extract which is still unexplored. Theoretically, if the anti-biofilm activity of the 
extract was due to the extract disrupting the formation or the extracellular matrix of the biofilm 
then it would not contribute to the antimicrobial activity.  
As mentioned above, HPLC characterisation of fraction 24 revealed that fucoxanthin 
was unlikely to be the active component within the M. pyrifera extract. Results indicated that 
there was a neglible amount of fucoxanthin within the active fraction, and that 1 mg/mL of 
commercial fucoxanthin showed no antimicrobial activity in the agar well diffusion assay. A 
previous study found that fucoxanthin purified from an H. elongata extract (25 µg) produced a 
ZOI (10.3 mm) against L. monocytogenes ATCC 19115 in an agar disk diffusion assay (43). In 
addition, Abou et al. (56), showed that fucoxanthin purified from Turbinaria triquetra (100 
µg/mL in EtOH), produced a ZOI against clinical isolates of S. aureus (5.3 ± 0.1 mm) and P. 
aeruginosa (5.6 ± 0.1 mm) (56). Further, Karpinski et al. (40) showed that fucoxanthin (in 20% 
DMSO) produced a ZOI (11.0 mm), and a MIC of 125 µg/mL in a microbroth dilution assay 
against the same strain of S. aureus (40). There are however discrepancies between these studies 
and this project, in the seaweed, solvent, concentrations, assay conditions and bacterial strains 
used (Table 4). Karpinksi et al. reported a MIC of 125 µg/mL against S. aureus, this 
concentration is much higher than the highest concentration of fucoxanthin in our microbroth 
dilution assays (25 µg/mL). We could not test fucoxanthin at a higher concentration due to 
limitations on the amount of fucoxanthin available. 
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GC analysis of the fraction 24 showed that the most abundant FFA was palmitic acid, 
suggesting that this may be the active compound. Previous literature has suggested that palmitic 
acid has antimicrobial activity against Gram-positive bacteria (58). Mendes et al. (58). found 
ethyl acetate extracts of Gracilaria vermiculophylla, Porphyra dioica and Chondrus crispus, 
demonstrated antimicrobial activity in an agar disk diffusion against bacterial strains such as S. 
aureus, including a clinical MRSA strain and a sensitive strain ATCC 6538 and P. aeruginosa 
ATCC 10145.  Following GC analysis of the lipid of these extracts, it was observed that the 
fatty acid profile was dominated by saturated fatty acids, such as palmitic acid (58).  Essential 
oil extracts from the terrestrial plant Cestrum diurnum, have a FFA profile dominated by 
saturated fatty acids, and in particular palmitic acid (59). These extracts (1000 mg/mL) 
demonstrated ZOI against a vancomycin sensitive clinical S. aureus strain (21 ± 1.527 mm) and 
P. aeruginosa (24 ± 0.577 mm)(59). Abou et al. (56) extracted palmitic acid from T. triquetra 
and at 100 µg/mL palmitic acid displayed a ZOI against S. aureus  (3.0 ± 0.1 mm). 
Contradictorily, Zheng et al. (60) found that only unsaturated fatty acids demonstrated any 
antimicrobial activity against bacterial strains in a broth microdilution assay. Saturated fatty 
acids, including palmitic acid, did not demonstrate any antimicrobial activity in this assay 
against either Gram-positive or Gram-negative bacteria (2 mM).  As with the findings of this 
project, antimicrobial activity of palmitic acid appears to be assay dependent. While palmitic 
acid was found to be dominant in the fatty acid profile of this M. pyrifera extract, there are other 
unidentified compounds within the extract that may also contribute to the antimicrobial activity, 
either individually or synergistically with palmitic acid.   
Interestingly, this study indicates the M. pyrifera extract and fraction exhibit 
antimicrobial activity against Gram-positive S. aureus, but not Gram-negative P. aeruginosa. 
Abou et al. (56) reported on the antimicrobial activity of MeOH extracts from a range of 
different seaweeds.  High concentrations of Ulva lactuca, Laurencia optusa and T. triquetra 
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extracts were more effective against Gram-positive bacteria such as S. aureus compared to 
Gram-negative bacteria, like P. aeruginosa (56). In general, because of differences in the 
bacterial cell wall, Gram-negative bacteria tend to be more resistant to certain antibiotics (61). 
Gram-positive bacteria have a thick layer of peptidoglycan within their cell wall which is more 
penetrable for antibiotics (62). Whereas, Gram-negative bacteria have a unique cell wall with 
negatively charged outer membrane (63). As the cell wall is a major target for antibiotics such 
as 𝛽- lactams, Gram-negative bacteria are resistant to many antibiotics. This also appears to be 
the case with the lipid-rich extract and fraction used in this study. 
Although the mechanism of action of the M. pyrifera extract against S. aureus, and 
potentially other Gram-positive bacteria is still unknown. The antimicrobial activity of palmitic 
acid is also relatively unexplored. A 1:1 mix of oleic acid and palmitic acid has, however, been 
shown to cause plasmolysis and thus, cell shrinkage (56). Plasmolysis causes cell death when 
the cell membrane is no longer a viable barrier (64). Other studies do not address palmitic acid 
directly, instead suggest that long chain saturated fatty acids inhibit the growth of Gram-
positive bacteria such as S. aureus (65). Proposed mechanisms of action for these FFAs  
include: lysis of the cell wall, disruption of cellular metabolism, and diffusion of essential 
metabolites out of the cell  (65).  
Limitations  
This project demonstrated preliminary evidence indicating that the M. pyrifera extract 
demonstrates antimicrobial effects. As with any natural product, each extraction and 
fractionation will yield an extract with similar, but never exactly the same, composition of 
compounds. Quantification of compounds with each independent extraction would be a 
lengthy, time-consuming processes. Testing biological reproducibility is an important process 
to ensure a biological effect is elicited with every batch of extract.  To provide the best chance 
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of reproducibility, a rigorous extraction methodology should be followed  (66). As well as the 
identification of all the active compounds that contribute to the antimicrobial activity within 
the extract. Berretta et al. (67) used three batches of standardised proprolis extract and used 
correlation anaylsis to determine there was a significant relationship between the three batches, 
indicating chemical reproducibility. HPLC was used to characterise the specific chemical 
markers within the batches of extract to demonstrate the batch to batch similarity (67).   
Due to time constraints insufficient biological replicates were conducted for the 
antimicrobial assays, an issue that can be solved with further experimentation. The 
quantification of anti-biofilm activity was also limited due to time constraints. The “gold 
standard” of biofilm quantification is crystal violet staining (68), but despite its popularity this 
method has limitations. This dye stains cell surface molecules that are negatively charged and 
polysaccharides within an extracellular matrix, but does not differentiate between live and dead 
cells, or between cells and the extracellular matrix. Crystal violet dye measures the amount of 
biofilm present with no regard for the viability or functionality of the biofilm (69). This study 
chose against the use of this dye due to the high levels of staining, which was unreadable by 
the plate reader, as well as the irreplicable nature of results. The high level of staining was likely 
due to the extract binding to the 96-well plate then taking up the dye despite the washing 
process. Previous literature has also reported use of crystal violet dye on P. aeruginosa was less 
suitable than on other bacterial strains, due to the large variation between absorbance readings  
(68, 70).  
A metabolic dye was used as well as crystal violet dye to verify the viability of the 
biofilm. Metabolic dyes such as tetrazolium 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-
[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT), the cheaper TTC and resazurin 
dyes, like PrestoBlue used in this project, are often used for quantification of viable cells within 
a biofilm  (68). These can quantify the viable, live cells within a biofilm. A reduction of viable 
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cells within a biofilm could reflect anti-biofilm activity due to killing or biofilm dispersal (68, 
71). Previous studies have reported large variation both within and between species when using 
XTT as a measure of biofilm abundance (72). The experimental data obtained through 
PrestoBlue and TTC quantification of biofilm growth in this project, was also inconclusive due 
to variations between and within experiments. The fluorescent readings from the PrestoBlue 
dye were also uncharacteristically low for both the control biofilms and the treated biofilms. 
Therefore, colony counting was the preferred method of biofilm quantification in this project. 
However, the time-consuming nature of this method was a limitation. In future studies more 
methods of biofilm quantification should be explored in order to optimize this. 
 
Future Directions 
FFAs, like palmitic acid, are lipophilic compounds that have low solubility in aqueous 
solutions (73). Low solubility means FFA diffusion through solutions like MHB media is 
limited, therefore, the amount of active compound that reached bacterial cells may also be 
limited. This may be a reason that no antimicrobial activity was seen in the microbroth dilution, 
as the lipids within the extract could not effectively act on the bacterial cells in the aqueous 
media. This could also explain the incomplete zone of inhibition in the agar well diffusion 
assays, as the FFAs within the extract could not diffuse properly through the agar. To improve 
the solubility and thus, delivery of the crude extract to the bacterial cell, previous studies have 
looked at using protein loading to improve solubility. This is not a new phenomenon, the human 
body uses proteins such as albumin to transport FFAs and other hydrophobic compounds 
through the serum to their target organ (74). Even when bound to protein, FFAs are capable of 
rapid exchange between the protein and the binding site on the cell (75).  Therefore, loading 
the crude extract onto bovine serum albumin (BSA), purified or in serum, may solve the 
solubility issues encountered in this project. Previous studies have employed this method to 
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improve solubility of the active compound within a drug, which generally lead to improved 
intended activity of the drug (76). The use of FBS in culture medium has also been explored, 
the albumin concentration in FBS is around 2.5 g/dL and the use of 10% FBS in medium has 
been suggested to alter FA levels (77). We only used 5% FBS in DMEM media, which could 
be why no effect was seen in our project.  Therefore, it would be interesting to explore the effect 
of using BSA or serum to transport the lipophilic crude extract in media or agar to the target 
bacteria in vitro. Evaluating whether improvement of the solubility and thus, diffusion of the 
crude extract would have an effect on antimicrobial and/or antibiofilm activity would be an 
interesting avenue to further investigate. 
To date there are no biofilm specific treatments, thus, making it important to continue 
to explore various therapeutic options to target biofilm infections. Although no significant 
decrease in bacterial numbers were detected in the MBEC screens for the S. aureus strains, a 
visible decrease was observed. Therefore, the anti-biofilm activity extract, and its isolated 
fraction, should be followed up on and further explored through more repeat experiments, 
perhaps at higher concentrations. Should these analyses confirm the anti-biofilm for the extract 
or fraction, the next step would be to assess their activity against a S. aureus and P. aeruginosa 
polymicrobial biofilm, to better replicate more complex bacterial infections (78). 
As bioactive fraction 24 shows strong antimicrobial potential it is important to identify 
which compounds within the extract are contributing to the observed effects. Further 
characterisation of the fraction could involve exploring other methods of extraction or 
fractionation. Kim et al. used ethyl acetate as a solvent for extraction on E. bicyclis. Ethyl 
acetate fractions usually contain flavonoids, tannins and phenolic compounds, which have also 
been found to demonstrate antimicrobial activity (37). Leyton et al. also provides another 
method to obtain the phlorotannin extract from M. pyrifera, using an enzymatic pretreatment 
and NaOH in the extraction (44). Thus, using methods, such as those previously described, to 
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identify the phlorotannin fraction of the M. pyrifera extract used in this study could allow for 
further characterisation.  
If an active compound is identified, it would then be important to evaluate this along-
side the M. pyrifera extract and fraction in an in vitro skin infection model, in order to evaluate 
the treatment in an environment that more closely resembles a human SSTI (79). A biofilm 
forming bacterial skin infection is infected onto an animal model to create an in vivo animal 
skin infection model, for a more physiologically comparable response compared to in vitro 
bacterial assays (80). Mohammed et al. found antimicrobial activity in novel synthetic thiazole 
compounds against different clinical MRSA strains using a murine skin infection model (80). 
In vitro skin models are also used to evaluate the antimicrobial activity of new therapies, these 
are considered more ethical than animal models. Shepard et al. created an in vitro skin model 
of a burn wound infected with S. aureus S-235 and P. aeruginosa SOM-1 (79). The authors 
tested the antimicrobial activity of their novel hyperbranched poly(N-isopropyl acrylamide) 
polymers on the burn model and found a reduction in bacterial biofilm burden (79). Thus, it 
would be interesting to further investigate the antimicrobial and anti-biofilm activity of the M. 
pyrifera extract on a more physiological skin infection model.  
Biofilm quantification was a limitation of this study. Future directions could explore 
different methods other than metabolic dyes and colony enumeration to improve this. Guo et 
al. used a bioluminescent imaging to quantify the bacterial burden present on a murine skin 
infection model (81). A bioluminescent strain of community acquired MRSA USA300 LAC 
was used and the number of bacteria present in the biofilms were examined using digital 
photographs to compare the bioluminescent signals between wound lesions (81). This also acts 
to determine cell viability within the biofilm, as only metabolically active, live cells will emit 
bioluminescence (81). Monzón et al also use ATP-bioluminescence to quantify Staphylococcus 
epidermidis the viable cells within the biofilm (82). Guo et al. also validated the 
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bioluminescence method of biofilm quantification with colony enumeration, by confirming the 
bioluminescent signals accurately correlated to the bacterial burden in vivo (81).  Thus, this 
project could also elicit a range of methods including fluorescent imaging, dyes and colony 




Bacterial SSTI infections range in their severity and complexity. This is further 
complicated by multi-drug resistant and biofilm-forming bacteria, with many common 
antibiotics prescribed to treat these infections now rendered useless. The demand for novel 
antimicrobials has spearheaded the search towards natural products, such as those derived from 
seaweed. This study found encouraging results that a M. pyrifera extract and fraction exhibit 
antimicrobial and anti-biofilm activity against two strains of S. aureus. Results suggest this 
extract shows promise as the basis for a novel antimicrobial treatment for bacterial SSTIs. It is 
worth conducting further research into the M. pyrifera extract, and its fractions, to gain a better 
understanding of their bioactive compounds and mechanism of antimicrobial and anti-biofilm 
activity. Seaweeds extracts therefore offer an exciting new avenue for the development of 
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